Cannabis Report
Home > Boards > US OTC > Miscellaneous >

Therapeutic Solutions International, Inc. (TSOI)

Add TSOI Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, subslover, centsability4me
Search This Board: 
Last Post: 5/23/2018 8:42:48 AM - Followers: 97 - Board type: Free - Posts Today: 2

Therapeutic Solutions International, Inc.

is a public company  focused on immune
modulation for the treatment of several specific diseases.

NEWS : 5/21/18
- Therapeutic Solutions International Releases "DermalStilbene" a Topical Formulation of Pterostilbene

Oceanside, CA -- May 21, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the availability of a topical form of pterostilbene called "DermalStilbene."

As previously stated, pterostilbene has been demonstrated in numerous publications to possess therapeutic effects in animal models of numerous inflammatory-associated conditions including cancer, diabetes, and heart failure, but it has also been shown to "protect hairless mice against UVB radiation-induced skin damage and carcinogenesis1", and "was able to reduce biofilm formation and kill the MRSA in immune cells by virtue of its strong antibacterial activity and facile delivery across biomembranes2"

"The release of this new product is meant to complement our other pterostilbene containing products such as ProJuvenol and NanoStilbene, and we are pleased to make this available to our customers for topical application," said Timothy Dixon, President, and CEO of Therapeutic Solutions International.

"Pterostilbene is a more potent form of resveratrol, which both activate similar molecular pathways including SIRT-1. This protein called a "sirtuin" is known to possess anti-aging effects based on laboratory studies3. While clinical studies have not been performed yet, it is not outside of the realm of possibility that pterostilbene based products may possess a beneficial effect on aging cells" said Dr. James Veltmeyer, Republican Congressional Candidate and Scientific Advisory Board Member of TSOI.

NEWS : 5/15/18 - Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant Nanostilbene

 OCEANSIDE, CA - May 15. 2018 -- Investors Hub Newswire -- Therapeutic Solutions  International ,Inc., (OTC Markets: TSOI) announced today Institutional Review Board (IRB) clearance to initiate a pilot pharmacokinetic trial of it's nanoparticle delivered pterostilbene product called "NanoStilbene."

"The initiation of a formal clinical trial evaluating the efficacy of the nanoparticles in NanoStilbene is a major milestone in the development of our product. Only through solid science can we be positioned to state exactly the advantages of the nano-formulation technology utilized in the manufacture of NanoStilbene," said Timothy Dixon, President, and CEO of Therapeutic Solutions International.

"Clinical trials are a fundamental part of developing any therapeutic agent. I am excited to be working with the Company on performing clinical trials on a nutraceutical, which demonstrates to me the commitment Therapeutic Solutions International has to develop superior nutraceuticals that can be integrated into standard medical practice," said Dr. James Veltmeyer, member of the Company's Advisory Board and Medical Monitor of the clinical study.

NEWS : 5/9/18 - Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board

Company to Iniate Investigational Cardiovascular Study with Dr. Azimi  and Nanostilbene

 May 09, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today that Nassir Azimi, M.D., has been appointed to the Company’s Scientific Advisory Board. In addition to this, Dr. Azimi plans to work with the Company to investigate the use of its product NanoStilbene in heart attack victims.

"I envision a world where NanoStilbene is an essential adjunct to standard medical treatment in patients with cancer and heart disease". Cardiovascular disease is a leading cause of death in the United States as well as worldwide.

" Dr. Azimi is a big proponent on the uses of antioxidants such as our nanoparticle pterostilbene product NanoStilbene, in cardiovascular patients, a product included in two of our cancer vaccines in use at the Pan Am Cancer Treatment Center in Tijuana, Mexico that we previously announced".

NEWS : 5/1/18 - Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment

Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene

OCEANSIDE, Calif., May 01, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire –Therapeutic Solutions International, Inc., (OTC Markets:TSOI) announced today signing of an agreement with the Pan Am Cancer Treatment Center covering production and clinical implementation of its patent pending StemVacs Platform in combination with our Patented immunological adjuvant NanoStilbene.

Having previously treated 10 patients with StemVacs in a proof-of-concept trial in collaboration with the Pan Am Cancer Treatment Center, we are very excited to expand the number of patients receiving this investigational immunotherapeutic approach,” said Timothy Dixon, President and Chief Executive Officer of TSOI. “Under Compassionate Use and Right to Try, we are able to offer this fee-for-service treatment not available anywhere else in the world and very pleased to do so and even more pleased that every patient treated will also be adding NanoStilbene to their personalized treatment protocol.”

link to Pan Am Cancer Treatment Centers website :

link to TSI's Patent covering NanoStilbene :

StemVacs is also the subject of a filed Investigational New Drug Application (IND #17448) with the U.S. FDA. The IND seeks to establish safety and immune response of cancer, targeting a new personalized dendritic cell vaccine.

link to TSI's StemVacs PR :

link to BORIS/StemVacs patent application :

This info covers the Pan Am clinical program :

TSI Facebook page :

Corporate website :
E-commerce site :
Additional information :

Nutraceutical division :

 Projuvenol®, is a Patented (No. 9,682,047) proprietary mixture containing pterostilbene – one of the most potent antioxidants known.

NanoStilbene 150ml

NanoStilbene, which is a form of pterostilbene containing nanoparticles, is covered for use in cancer immunotherapy under the Company’s issued U.S. Patent No.: 9,682,047.
DermalStilbene 60ml
DermalStilbene - a topical formulation of pterostilbene

Subsidiaries : 

SandBox Dental Labs, Inc. – is a majority owned subsidiary of TSI consisting of a dental laboratory to manufacture and fill prescriptions from dentists who will use our proprietary Sleep Appliance to treat their patients with mild to moderate obstructive sleep apnea.

Emvolio, Inc. – is a majority owned subsidiary of TSI where the intellectual property surrounding immune-oncology is housed.  The Company is developing products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies


 Share Structure :
7,495,215  - (as of 05/21/2018)
AS - 990 M (as of 7/7/17)
OS - 832,801,713 (as of 4/17/18)
Float - 46,317,028 (as of 7/7/17)
SEC Filings :

Patents :
Patent Filed  Patent Name Press Release
 07-08-15  Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions  07-09-15
 07-21-15  Prevention of Pregnancy Complications by Probiotic Administration 07-22-15
 09-02-15  Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications 09-08-15
 09-15-15  Diagnostic Methods For The Assessment Of Pregnancy Complications 09-21-15
 09-25-15  A Medical Device For Reducing The Risk Of Preterm-Labor And Preterm-Birth 09-29-15
11-20-15  Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer 11-23-15
04-27-16  Augmentation Of Stem Cell Activity Using Ppterostilbene And Compositions Containing Pterostilbene  04-28-16
 03-29-17  Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization 04-10-17
 03-29-17  Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants  05-09-17
 03-29-17  Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients  05-16-17
 03-29-17  Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof 05-22-17
 03-29-17  Methods of Re-Activating Dormant Memory Cells with Anticancer Activity 06-05-17
 10-08-17 Synergistic Inhibition of Glioma Using Pterostilbene and Analogues Thereof 10-16-17

Management and Board of Directors


Timothy G. Dixon – President, CEO, & Chairman

Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. Mr. Dixon also serves as President and Chairman of OmniBiome, Inc.,and President. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. Mr. Dixon has attended hundreds of hours of continuing medical/dental education throughout the years and has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies.

Gerry B. Berg – Vice President, CFO, Director

Gerry B. Berg has served as our Vice-President and Chief Financial Officer since April 20, 2011.  Mr. Berg became a director of the Company on August 24, 2012.  Mr. Berg has over 30 years of senior management experience working with private and public companies.  From May 2010 to March 2011, Mr. Berg served as President and Chairman of the Board of Directors of Friendly Auto Dealers, Inc. and also served in a consulting capacity from March 2009 to May 2010.

Mr. Berg holds a Bachelors of Science in Accounting from Walsh College where he graduated Cum Laude.  Mr. Berg became a Certified Public Accountant in the State of Michigan in 1979 and in the State of California in 1984.  Mr. Berg does not currently practice as a Certified Public Accountant.

Thomas E.Ichim, Ph.D – Director

Dr. Ichim was appointed to the Board of Directors on January 22, 2016.  Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date he has published 99 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”

Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr Ichim is inventor on over 50 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.

Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, a MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

Hong Ma, MD, Ph.D., M.B.A. – Chief Scientific Officer

Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.

Scientific Advisory Board Members

Dr. Santosh Kesari is a board-certified neurologist and neuro-oncologist and is currently Chair, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute.

He is also Director of Neuro-Oncology, Providence Saint John’s Health Center and Member, Los Angeles Biomedical Research Institute. Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal. He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books. He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences focused biotech startups.

Dr. Kesari has had a long-standing interest in cancer stem cells and studies their role in the formation of brain tumors and resistance to treatment. He believes that in order to cure patients with brain tumors we first need to gain a better molecular and biological understanding of the disease. A physician/scientist, Kesari harnesses his experience in surgery, chemotherapy, immunotherapy, radiation therapy and novel devices to help develop Precision Therapeutic Strategies that will advance medicine to a new stage in the battle against brain tumors and eradicate the disease.

Dr. Pablo Guzman is a cardiologist in Fort Lauderdale, Florida where he is on staff at Holy Cross Hospital. He received his medical degree from University of Puerto Rico School of Medicine and his Cardiology Fellowship at The Johns Hopkins Hospital where he then spent the first part of his career continuing his basic science and clinical research along with his clinical duties. His CV includes over 25 papers published in peer reviewed journals and more than 15 abstracts.

He is a Fellow of the American College of Cardiology and practiced for more than 30 years. Dr. Guzman is well experienced in basic and clinical research, having participated in many clinical trials. He is also the acting Chief Medical Officer of Variant Pharmaceuticals, a Specialty Pharma company developing treatments for kidney diseases.

Dr. Nassir Azimi is a cardiologist in La Mesa, California and attended Dartmouth Medical School and completed his residency at the University of Colorado. He finished his four year fellowship in Cardiovascular and Peripheral Interventions at Yale University in New Haven. Dr. Azimi has been in private practice for over 13 years establishing a thriving clinical practice for cardiac patients as well as treating patients for peripheral vascular disease. He is active in Interventional Cardiology and Peripheral Interventions. Dr. Azimi is the director of La Mesa Cardiac Center’s Nuclear Cardiology Laboratory. He is also an investigator in multiple clinical research studies for various cardiac and peripheral diseases.

He has been recognized as San Diego’s Top Interventional Cardiologists by San Diego Magazine 2013,2014,2016, 2017 and also by Castle Connoly for 2013, 2014, 2015,2016, 2017, and 2018. He is a former chief of biomedical ethics (6 years), former chief of Medicine and former chief of Endovascular Medicine as well as Vice Chief of Cardiology at SGH. He is on the board of directors of the California ACC where he serves as chair of the public relations committee. He is on Editorial Review Board for multiple medical journals. He is a national speaker on various topics in cardiology and internal medicine.

Dr. James Veltmeyer, is a board certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing 36 doctors.

Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the most prestigious honor awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

Dr. Barry Glassman, DMD, DAAPM, DAACP, FICCMO, Diplomate ABDSM, FADI, is a Diplomate of the American Academy of Craniofacial Pain and the American Academy of Pain Management, as well as a Fellow of the International College of Craniomandibular Orthopedics and the Academy of Dentistry International, he is also on staff at the Lehigh Valley Hospital where he serves as a resident instructor of Craniofacial Pain and Dysfunction and Dental Sleep Medicine.

Dr. Glassman is a Diplomate of the Academy of Dental Sleep Medicine. He is on the staff at the Sacred Heart Hospital Sleep Disorder Center, as well as serving as the Chief Dental Consultant to three other sleep centers in the Lehigh Valley. A popular and dynamic speaker, Dr. Glassman lectures internationally, as well as throughout the United States. In addition to his extensive schedule which includes guest lecture appearances and in-depth courses on joint dysfunction, chronic pain, headache, sleep disorders, and migraine headache, Dr. Glassman is a frequent speaker at major chronic pain and joint dysfunction professional conferences.

University of Pittsburgh: Bachelor of Science 1969, Pittsburgh, Pennsylvania University of Pittsburgh School of Dental Medicine; D.M.D. 1973, Pittsburgh Pennsylvania Post Graduate Hours in Craniomandibular Dysfunction and Sleep Disorders: Over 2500

Dr. Vijay Mahant has been involved in Research and Development in the medical industry for close to 30 years. Working in the FDA regulated medical industry, he has headed R&D activities for several bio-medical companies as well as being the founder, CEO & Chairman of MediLite, Inc.

Dr. Mahant has specialized in the areas of assay development, has numerous patents to his credit and has published extensively. Dr. Mahant received his B.S. in Biochemistry from the University of Salford, UK; a M.S. in Medicinal Chemistry and a Ph.D. in Medical Biochemistry from Lougborough University of Technology, UK.

Dr. David P. Hajjar is currently Professor of Biochemistry, at Weill Cornell Medical College and Professor of Pathology and Laboratory Medicine, Weill Cornell Medical College.

Professor Hajjar was also a Frank H.T. Rhodes Distinguished Professor of Cardiovascular Biology and Genetics, Pathology and Laboratory Medicine, Weill Cornell Medical College from 1998 – 2014. Currently Dr. Hajjar is Dean Emeritus and was Executive Vice Provost at Cornell University.

The principal aim of Dr. Hajjar’s work is to define the mechanisms by which Nitric Oxide (NO) and prostaglandin synthetic pathways interact to alter eicosanoid biosynthesis as well as to investigate the impact of these mediators on atherosclerosis and thrombosis. Over the years, he has defined the roles and mechanisms of these complex signaling interactions in order to gain an understanding of the pathophysiological processes in atherosclerosis using animal models and the consequences of pharmacological interventions.

In recent work, he has showed that the enzyme prostaglandin H2 synthase (PGHS, also known as cyclooxygenase) regulates the production of eicosanoids that modulate physiologic processes in the vessel wall, contributing to atherosclerosis and thrombosis. Dr. Hajjar demonstrated that various forms of NOx can have different modulatory effects on the activity of PGHS-1, the predominant isozyme in platelets. These and other studies revealed that the active heme center of PGHS-1 regulates peroxynitrite-induced modification and loss of enzyme reactivity, indicating that heme may play a decisive role in catalyzing these processes in PGHS-1 when exposed to nitrative stress in an inflammatory setting. Collectively, these studies show for the first time that iNOS influences PGHS expression and its activity, which can contribute to modification of an important enzyme involved in inflammation during atherosclerosis. Since iNOS-derived species are required for robust atherosclerosis-associated peroxynitrite production in peripheral organs, these studies have contributed importantly to our understanding of the complex alterations in eicosanoid metabolism that occur during the pathogenesis of heart disease where inflammation occurs.

Contact :
E - mail :
Address : 
4093 Oceanside Blvd.
Suite B
Oceanside , CA
Phone :
(760) 295 - 7208

Disclaimer : All of the information presented in the IBOX , Stickies , or posts on this board ,  is based on individual opinions , and is not to be considered as a recommendation to buy , sell , or hold this stock .

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TSOI News: Amended Quarterly Report (10-q/a) 05/22/2018 03:17:44 PM
TSOI News: Quarterly Report (10-q) 05/21/2018 04:46:11 PM
TSOI News: Therapeutic Solutions International Releases "DermalStilbene" a Topical Formulation of Pterostilbene 05/21/2018 09:00:00 AM
TSOI News: Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant Nanostilbene 05/15/2018 09:00:00 AM
TSOI News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 05/11/2018 02:43:23 PM
News News Alert: Amended Quarterly Report (10-q/a) 05/22/2018 03:17:44 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#6198   Research Patent applied for and protection granted centsability4me 05/23/18 08:42:48 AM
#6197   They have medicine bottle 300$ and less price kubis 05/23/18 08:09:30 AM
#6196   To low .. sharkey12 05/22/18 02:47:16 PM
#6195   after quarterly report, it is always negative. corvatsch 05/22/18 02:34:39 PM
#6194   I agree. Chaka 05/22/18 02:24:13 PM
#6193   TSOI needs some kind of black buster news Abbas14 05/22/18 02:11:54 PM
#6192   TSOI DD Updated centsability4me 05/22/18 08:48:34 AM
#6191   5/21 NEWS centsability4me 05/22/18 08:28:31 AM
#6190   NEWS! Chaka 05/21/18 09:44:39 PM
#6189   I say we hold up very today's. Chaka 05/21/18 07:17:01 PM
#6188   Extra Credit centsability4me 05/21/18 07:02:54 PM
#6187   We will be soon. Chaka 05/21/18 01:02:04 PM
#6186   TSOI is over a penny yet??? Hummm Abbas14 05/21/18 12:23:26 PM
#6185   DermalStilbene what are the future apps. ? centsability4me 05/21/18 11:19:43 AM
#6184   GM FELLOW TSOIers! Chaka 05/21/18 09:28:25 AM
#6183 take a look centsability4me 05/21/18 09:12:03 AM
#6182   $TSOI: DermalStilbene being sold for $60 for 60mL bottle makinezmoney 05/21/18 09:10:29 AM
#6181   TSOI NEWS out! subslover 05/21/18 09:04:28 AM
#6180   ***NEWS 5/21/18*** centsability4me 05/21/18 09:04:08 AM
#6179   News out on the wire sharkey12 05/21/18 09:03:50 AM
#6178   TSOI centsability4me 05/20/18 02:42:55 PM
#6177   MARKET CAP centsability4me 05/20/18 12:32:11 PM
#6176   TSOI $$$ .. can’t wait to see this Abbas14 05/20/18 08:41:12 AM
#6175   Smart move, the pps targets here are just stockyupydowny 05/18/18 09:47:13 PM
#6174   U 2 brother! Chaka 05/18/18 06:58:09 PM
#6173   2 days in row with NO T_TRADES. This subslover 05/18/18 04:38:08 PM
#6172   next week , centsability4me 05/18/18 03:11:20 PM
#6171   Quiet today .. hope next week more activity here sharkey12 05/18/18 03:08:40 PM
#6170   Boris is much older than 2006 centsability4me 05/18/18 02:24:07 PM
#6169   the science centsability4me 05/18/18 01:34:51 PM
#6168   The Company CEO only has the smartest Scientists subslover 05/18/18 12:28:09 PM
#6167   that would be nice sharkey12 05/18/18 12:22:59 PM
#6166   Got out of the other one CEL* at subslover 05/18/18 12:09:36 PM
#6165   It’s a bit under the radar at the wedman 05/18/18 12:04:43 PM
#6164   TSOI has a much much smaller Public Float. subslover 05/18/18 11:31:52 AM
#6163   $$$ will be pouring in here soon. Chaka 05/18/18 11:18:44 AM
#6162   Folks will make the connection eventually jmmatthews67 05/18/18 10:51:04 AM
#6161   Yep ! That is why I’m here ! wedman 05/18/18 10:48:15 AM
#6160   Action here should follow CEL* but delayed a jmmatthews67 05/18/18 10:47:10 AM
#6159   GM FELLOW TSOI! Chaka 05/18/18 10:46:06 AM
#6158   Let's go ... sharkey12 05/18/18 10:12:42 AM
#6157   yesterday's vol. was good centsability4me 05/18/18 09:40:43 AM
#6156   Not sure about today, but hoping for good sharkey12 05/18/18 09:25:49 AM
#6155   TSOI DD UPDATED centsability4me 05/18/18 07:01:49 AM
#6154   TSoi looking good $$$ . Slowly and surely Abbas14 05/18/18 06:30:19 AM
#6153   CENTS, I sell to 0,04-0,05... corvatsch 05/18/18 05:19:35 AM
#6152   i know , centsability4me 05/17/18 08:14:35 PM
#6151   Zoonamied , centsability4me 05/17/18 07:56:22 PM
#6150   there are mo things comin, centsability4me 05/17/18 05:39:39 PM
#6149   What caught my eye was the pre-market volume X-ray07 05/17/18 05:30:29 PM